Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
07/2006
07/20/2006US20060160139 Rhesus BCRP and antibodies thereto
07/20/2006US20060160135 SF-1 and LRH-1 modulator development
07/20/2006US20060160133 Glucose-transport related genes, polypeptides, and methods of use thereof
07/20/2006US20060160130 Recombinant RSV virus expression systems and vaccines
07/20/2006US20060160126 90 human secreted proteins
07/20/2006US20060160118 Comprises muropeptides which activate nuclear factor kappa B; drug screening; inflammatory bowel diseases; Nucleotide sequences coding protein for use in the treatment of crohn's disease
07/20/2006US20060160103 Mammalian neuralized family transcriptional regulators and uses
07/20/2006US20060160094 Determining appropriate treatment of a neoplasia by comparing a p53 gene or transcript in a human tumor sample to a wild-type p53 gene or a transcript having a size of 2.8 kb in normal human tissue and identifying the differences
07/20/2006US20060160091 Polynucleotides encoding a class II cytokine receptor
07/20/2006US20060160090 Composition splice variants and methods relating to cancer specific genes and proteins
07/20/2006US20060160082 Novel genes and proteins encoded thereby
07/20/2006US20060160080 Avian sex determination method
07/20/2006US20060160076 Methods of treating and diagnosing diabetes with cx3cr1 modulators
07/20/2006US20060160067 GBV-B polynucleotide coding a virus having domain III of the 5' neurotrophin region from a hepatitis C virus 5' NTR, and at least part of a structural or non-structural protein coding region of HCV; viral expression construct; infectious GBV-B molecular clone
07/20/2006US20060159709 Recombinant high molecular weight major outer membrane protein of moraxella
07/20/2006US20060159708 Vascular Leak Syndrome; polypeptide toxophore from a DT; has cytotoxicity comparable to that of a DT molecule
07/20/2006US20060159707 Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses
07/20/2006US20060159705 Purification of HBV antigens for use in vaccines
07/20/2006US20060159704 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents
07/20/2006US20060159703 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
07/20/2006US20060159701 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
07/20/2006US20060159700 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
07/20/2006US20060159699 Dengue viruses useful for vaccination against Flavivirus; Modified Vaccinia Virus Ankara (MVA); stable, can easily be produced
07/20/2006US20060159696 Neutralizing epitope-based growth enhancing vaccine
07/20/2006US20060159692 Transcriptional factor inducing apoptosis in cancer cell
07/20/2006US20060159691 Ptprk immunogenic peptide
07/20/2006US20060159687 Modified aerolysin and methods of use for treating lung cancer
07/20/2006US20060159686 Natural killer cell activating factor II
07/20/2006US20060159685 Of given sequence; immunomodulators; prophylaxis or treatments for cancers
07/20/2006US20060159684 Compositions and methods for the threatment of sepsis
07/20/2006US20060159672 Identification of self and non-self antigens implicated in autoimmune diseases
07/20/2006US20060159662 Therapeutic anti-melanoma compounds
07/20/2006US20060159659 RNA picornavirus; selectively kills some types of tumors; making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms
07/20/2006US20060159654 Interacting the immature dendritic cells with an antigen ex vivo so that the surface antigen is presented; inducing maturation ex vivo; and contacting with a modulator comprising TRANCE; an increased viability relative to a control dendritic cell not contacted with TRANCE
07/20/2006US20060159652 Gd2 ligands
07/20/2006US20060159620 Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
07/20/2006DE102005001191A1 Vorrichtung und Verfahren zur Fraktionierung von Mono- und/oder Oligosaccharid-Strukturen Device and method for the fractionation of the mono- and / or oligosaccharide structures
07/20/2006DE102005001054A1 Tumorantigene für therapeutische und diagnostische Zwecke Tumor antigens for therapeutic and diagnostic purposes,
07/20/2006CA2603630A1 Modified exendins and uses thereof
07/20/2006CA2594934A1 C5a receptor antagonists
07/20/2006CA2594728A1 Maize cyclo1 gene and promoter
07/20/2006CA2593779A1 Li-key/antigenic epitope hybrid peptide vaccines
07/20/2006CA2593697A1 Pan-her antagonists and methods of use
07/20/2006CA2593464A1 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and uses thereof
07/20/2006CA2584812A1 Process for constructing strain having compactin hydroxylation ability
07/19/2006EP1681568A1 Artificial antibody comprising complementary peptide
07/19/2006EP1681565A1 Cellular RhoGTPase activation assay
07/19/2006EP1681353A1 Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
07/19/2006EP1681351A1 Bacillus thuringiensis CryET29 compositions toxic to coleopteran insects and Ctenocephalides Spp.
07/19/2006EP1681350A2 Porphorymonas gingivalis polypeptides and polynucleotides
07/19/2006EP1681349A2 Genetic control of plant growth and development
07/19/2006EP1681348A1 MU-1 member of the cytokine receptor family
07/19/2006EP1681305A2 Monoclonal and chimeric antibodies specific for human tumor necrosis factor
07/19/2006EP1681304A2 Recombinant fusion proteins of growth hormone and serum albumin
07/19/2006EP1681303A1 HASylated polypeptides, especially HASylated erythropoietin
07/19/2006EP1681302A1 Novel protein and production process and use thereof
07/19/2006EP1681301A1 Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
07/19/2006EP1681300A1 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS
07/19/2006EP1681299A2 Methods for purifying highly anionic proteins
07/19/2006EP1681298A2 Methods for purifying highly anionic proteins
07/19/2006EP1680678A1 Recombined cell system for deorphanizing g protein-coupled receptors
07/19/2006EP1680507A2 Bacterial expression of protease inhibitors and variants thereof
07/19/2006EP1680506A1 Meg1 endosperm-specific promoters and genes
07/19/2006EP1680505A1 Bace455, an alternative splice variant of the human beta-secretase
07/19/2006EP1680503A1 Recombinant production of antimicrobial agents
07/19/2006EP1680499A2 Modulation of angiogenesis by bartonella henselae
07/19/2006EP1680447A2 Orthogonal gene switches
07/19/2006EP1680446A2 Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
07/19/2006EP1680445A1 Polyvalent allergy vaccine
07/19/2006EP1680444A1 New soluble and stabilized trimeric form of gp41 polypeptides
07/19/2006EP1680443A2 Stabilized alpha helical peptides and uses thereof
07/19/2006EP1680439A2 Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
07/19/2006EP1680437A2 Motoneuronotrophic factor gene sequences
07/19/2006EP1680136A1 Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics
07/19/2006EP1680073A2 Compounds and method for treating cancer
07/19/2006EP1680009A2 Compositions and methods for diagnosing and treating mental disorders
07/19/2006EP1623038A4 Process for manufacture of nematode-extracted anticoagulant protein (nap)
07/19/2006EP1616183A4 Methods of detecting neurological disorders
07/19/2006EP1497646A4 Peptide biomarker and method of identification
07/19/2006EP1492809A4 Compositions and methods for evaluating and designing nuclear receptor ligands that modulate co-regulator affinity
07/19/2006EP1492476B1 Device for mixing and/or injecting cements
07/19/2006EP1463812A4 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli
07/19/2006EP1442058B1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
07/19/2006EP1404428B1 Methods for purifying highly anionic proteins
07/19/2006EP1379695B1 New polynucleotides and polypeptides of the ifnalpha-21 gene
07/19/2006EP1375667B1 Rice-origin high expression polypeptide chain elongation factor promoter and method of using the same
07/19/2006EP1282712B1 Synthetic gagpol genes and their uses
07/19/2006EP1276880B1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
07/19/2006EP1255815B1 Porcine reproductive and respiratory syndrome virus and methods of use
07/19/2006EP1179588B9 Human brain carboxypeptidase b
07/19/2006EP1163363B1 Compositions and methods for monitoring the modification of natural binding partners
07/19/2006EP1076566B1 Attenuated mutants of salmonella which constitutively express the vi antigen
07/19/2006EP1075492B1 Melanocortin 1 receptor selective compounds
07/19/2006EP1015561B1 In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
07/19/2006EP0988314B1 Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
07/19/2006EP0966481B1 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
07/19/2006EP0898580B1 Methods and means for inhibition of cdk4 activity
07/19/2006EP0835447B1 Novel peptides and compositions which modulate apoptosis
07/19/2006EP0831923B1 Separation of active complexes
07/19/2006EP0690724B1 Chlamydia vaccine comrising anti-idiotypic antibodies